Jefferson University Hospitals

Provider Profile

Pierluigi  Porcu, MD

Pierluigi Porcu, MD

Jefferson University Physician

Academic Title: Professor
Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation

Specialties
Medical Oncology
Medical Oncology - Hematologic Malignancies
Medical Oncology - Leukemia/Lymphoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-9641

Medical Services

Board Certifications

  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2018

Personal Statement

I am a Physician Scientist focused on T/NK-cell lymphomas and EBV-associated lymphomas. My goal is to offer patients a roadmap to understand their illness, find the determination to fight, select the best treatment and move forward with confidence. My overarching principle is patient empowerment based on knowledge. The more people know, the more prepared they are to face adversities. Knowledge guides expectations and grounds hope in facts. Great cancer care is based on compassion and research.

Education

  • Univ di Torino, Italy, Medical School

Internship

  • Indiana University Medical Center

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amer Assoc Retired Persons (AARP)
  • AmeriHealth
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Blue Cross/Blue Shield of Delaware
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Delaware Blue Cross/Blue Shield
  • Devon
  • Empire BC/BS
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medallion of New Jersey
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • NJ Plus
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

Duvelisib, a novel oral dual inhibitor of PI3K-d,g, is clinically active in advanced hematologic malignancies

Activity of the PI3K-δ,g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma

Editorial: Murine models of leukemia and lymphoma

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome

Expanding and expounding the genomic map of CTCL

A positive randomised trial in cutaneous T-cell lymphoma

Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas

Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL)

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

Overview of the use of murine models in leukemia and lymphoma research

Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?

MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

Sézary Syndrome: Clinical and Biological Aspects

Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma

NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines